New pain drug could cut opioid use after tummy tucks

NCT ID NCT07102459

Completed Symptom relief Sponsor: Latigo Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called LTG-001 for managing pain after a tummy tuck (abdominoplasty). 343 adults took either a high or low dose of LTG-001, a standard painkiller combination, or a placebo. Researchers measured pain relief over 48 hours and tracked how much extra opioid pain medication was needed. The goal was to see if LTG-001 works and is safe for short-term post-surgical pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LTG-001 (an experimental painkiller)
What this could lead to: If it works, this could provide a new option for managing short-term pain after surgery, possibly reducing the need for opioid painkillers.
What could go wrong: This is an early Phase 2 trial, so results may not confirm effectiveness or safety. The drug is only tested for 48 hours after one type of surgery, so it may not work for other pain types or longer periods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PAIN POSTOPERATIVE PAIN CONTROL

Contacts and locations

Locations

Arizona Research Center

Phoenix, Arizona, 85053, United States
CenExel ACMR

Atlanta, Georgia, 30331, United States
Endeavor Clinical Research

San Antonio, Texas, 78240, United States
HD Research LLC

Houston, Texas, 77043, United States
JBR Clinical Research (CenExel)

Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.